Table 2 General characteristics of reports with faricimab from the FAERS and JADER database

Number of events

4234

142

Gender

 Female

1707

40.3

53

37.3

 Male

1524

36

78

54.9

 Missing

1003

23.7

11

7.7

Weight

 <50 kg

17

0.4

4

2.8

 50–80 kg

196

4.6

28

19.6

 >80 kg

135

3.2

1

0.7

 Missing

3886

91.8

109

76.8

Age

 <18 years

93

2.2

–

–

 18–40 years

70

1.7

–

–

 41–60 years

483

11.4

11

7.7

 61–80 years

1332

31.5

81

57

 ≥81 years

563

13.3

40

28.2

 Missing

1693

40

10

7

Occupation

 Medical doctor

2478

58.5

137

96.5

 Consumer

1401

33.1

1

0.7

 Health Professional

271

6.4

1

0.7

 Pharmacist

77

1.8

3

2.1

 Missing

7

0.2

0

0

Report country

 United States

2167

51.2

–

–

 India

333

7.9

–

–

 Japan

284

6.7

142

100

 Canada

232

5.5

–

–

 France

175

4.1

–

–

 United Kingdom

173

4.1

–

–

 Australia

140

3.3

–

–

 Korea, South

121

2.9

–

–

 Germany

90

2.1

–

–

 South Africa

59

1.4

–

–

Outcome

 Hospitalization

170

4

–

–

 Death

129

3

5

3.5

 Disability

52

1.2

–

–

 Life-threatening

17

0.4

–

–

 Required Intervention

5

0.1

–

–

Outcome

 Congenital anomaly

2

0

–

–

 Partially Recovered

–

–

40

28.2

 Recovered

–

–

37

26.1

 Not Recovered

–

–

35

24.6

 Sequelae Present

–

–

6

4.2

 Other

639

15.1

–

–

 Missing

1014

23.9

19

13.4

Indications(top five)

 Neovascular age-related macular degeneration

1354

32

83

58.5

 Product used for unknown indication

879

20.8

–

–

 Diabetic retinal oedema

603

14.2

39

27.5

 Age-related macular degeneration

225

5.3

17

12

 Retinal vein occlusion

202

4.8

1

0.7

 Polypoidal choroidal vasculopathy

–

–

2

1.4